蛋白质组风险评分用于预测事件高血压的预测
Minkwan Kim1, Hamed Tavolinejad2,3, Mateo Bustamante2,3
1Division of Cardiology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Republic of Korea (M.K.).
Hypertension (Dallas, Tex. : 1979)
|February 20, 2026
概括
一个新的蛋白质基因风险评分 (ProtRS) 显著改善了发生高血压的预测,超过了传统的风险因素和遗传数据. 这种蛋白质组方法提供了增强的高血压风险分层和对疾病机制的洞察力.
科学领域:
- 心血管疾病研究研究
- 蛋白质组学和生物标志物发现发现
- 精准医学是一门精准的医学.
背景情况:
- 蛋白质组签名在预测心脏代谢疾病方面表现有前途.
- 准确预测事件高血压对于有针对性的预防策略至关重要.
研究的目的:
- 评估蛋白质组风险评分 (ProtRS) 是否提高了发生性高血压的预测.
- 评估ProtRS的附加值,超出已确定的人口,临床和遗传风险因素.
主要方法:
- 在英国生物银行蛋白质组队列 (n=25,158) 中使用受罚的考克斯回归来开发了ProtRS.
- 在独立的英国生物库测试组 (n=10,781) 和Asklepios研究 (n=793) 中验证了ProtRS.
- 通过比较具有和没有ProtRS的风险预测来评估模型性能,包括对共变量和多基因风险得分 (PRS) 的调整.
主要成果:
- 在英国生物库中,较高的ProtRS与事件高血压有很强的关联 (HR, 1.68).
- 添加ProtRS显著改善了模型匹配,歧视 (C指数从0.745增加到0.765) 和重新分类 (NRI,19%).
- 在Asklepios的外部验证证实了ProtRS与高血压风险 (HR, 1.32) 的相关性,并改善了模型歧视.
结论:
- 蛋白质组风险评分 (ProtRS) 显著提高了超越当前人口统计,临床和遗传信息的事件高血压的预测.
- 蛋白质组数据为个性化高血压风险分层提供了有价值的工具.
- 途径分析表明对高血压发展的生物学见解,包括中性粒细胞脱粒和PI3K信号传递.
相关概念视频
Hypertension II: Pathophysiology
1.1K
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.1K
Genome-wide Association Studies-GWAS
15.8K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
15.8K
Hypertension III: Clinical Manifestations and Diagnostic Studies
640
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
640
Hypertension I: Introduction
1.0K
Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
1.0K
Hypertension and Regulation of Blood Pressure
4.5K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
4.5K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
625
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
625

